FDA-CMS Parallel Review: Why Clearance Isn't Coverage

FDA market authorization and Medicare coverage are decided by two different agencies, under two different statutes, on two different clocks. A device can clear FDA review and still sit for a year or longer before Medicare decides whether to pay for it — because the National Coverage Determination process that CMS runs doesn't start until FDA finishes. A standing FDA-CMS program exists to close that gap for eligible devices. Most sponsors never ask whether their device qualifies for it — they find out about the gap only after FDA clearance, when the market-access team discovers Medicare coverage was never automatic.

Why the gap exists

FDA's premarket decision asks whether a device is safe and effective for its intended use. CMS's coverage decision asks whether Medicare will pay for it — a separate analysis under the Social Security Act, run through either a national coverage determination or, absent one, decisions made contractor by contractor through local coverage determinations. Historically, that second process didn't start in earnest until the first one finished, so sponsors who treated FDA clearance as the finish line discovered the real finish line was still a year or more away. The gap is structural, not a processing delay either agency can simply work faster through — it exists because the two decisions ask genuinely different questions of genuinely different evidence.

What the Parallel Review program actually does

FDA and CMS piloted the Program for Parallel Review of Medical Devices starting in November 2011, accepting requests for two years and capping participation at a small number of sponsors annually. In October 2016, the agencies converted it into a permanent, indefinite program. The mechanics haven't changed: FDA and CMS review the same device's data concurrently, each reaching its own decision under its own statutory authority, instead of CMS waiting for FDA's decision before starting its own clock. The agencies have described candidates as devices built on new technology, routed through a PMA or De Novo request, with either an approved Investigational Device Exemption or substantial pre-IDE interaction with FDA already underway — evidence that the device isn't an unknown quantity walking into two review processes at once.

• New technology on a PMA or De Novo pathway. The program is not built for incremental changes to an existing predicate or for De Novo candidates that look like routine reclassifications.
• An established FDA record. A sponsor requesting parallel review is expected to already have an approved IDE or meaningful pre-IDE engagement — the program accelerates a relationship that already exists, it doesn't create one from a cold start.
• One evidence plan, two audiences. The clinical evidence package has to be built to answer FDA's safety-and-effectiveness question and CMS's coverage question at the same time, which is a different negotiation than optimizing for FDA alone.
• Confirm current volume limits. The original pilot capped participation at a handful of sponsors per year; verify directly with FDA and CMS whether a cap still applies to the permanent program before building a timeline around guaranteed entry.

Sponsors who plan for FDA clearance and treat Medicare coverage as a formality discover, usually after the fact, that the two were never on the same clock to begin with. Why parallel review has to be a pre-IDE decision, not a post-clearance one

RAPID: a narrower pathway, still proposed

In April 2026, FDA and CMS announced a newer, more targeted pathway — referred to as the RAPID coverage pathway — aimed specifically at FDA-designated Breakthrough Devices that are also enrolled in a qualifying IDE study reaching Medicare beneficiaries. As described, CMS would issue a proposed national coverage determination the same day a qualifying device receives FDA market authorization, starting the statutory comment period immediately rather than after a separate CMS review cycle begins. That is a materially faster design than the 2016 program, but it is a proposal: confirm whether it has reached final status, and under what finalized eligibility criteria, before treating it as available. A Breakthrough-designated device still gets real protection from the permanent Parallel Review program in the meantime — RAPID is worth tracking, not worth waiting for.

None of this is exotic, but it has to start before the PMA or De Novo strategy is locked, because the pre-IDE record parallel review expects is built during exactly the window most teams are focused entirely on FDA. Companies that treat market access as a question for after clearance are the ones who discover, months into a coverage review they didn't know was independent, that the real commercial launch clock was never the one FDA started. Building the parallel-review decision into the pre-IDE plan — rather than the market-access team's to-do list after the approval letter arrives — is what keeps the gap from becoming a surprise.